Welcome to the Oncology Brothers podcast and our new series, Rapid Fire Rounds! In this episode, we were joined by Dr. Joseph Mikhael, a myeloma specialist from the City of Hope, to answer 10–12 community-sourced questions on multiple myeloma management.

The panel covers:

Frontline therapy: Quadruplet therapy, carfilzomib vs bortezomib, and high-risk disease definitions
Maintenance strategies: Lenalidomide alone vs daratumumab-lenalidomide vs carfilzomib-lenalidomide, with insights from the ENDURANCE, ATLAS trials
Relapsed/refractory disease: Sequencing CAR T-cell therapy, bispecific antibodies (teclistamab + daratumumab), and the newly approved cereblon modulators (CELMoDs) like mezigdomide
CAR-T logistics: The critical distinction between holding therapy (pre-collection) and bridging therapy (post-collection)
Supportive care: IVIG, antiviral/antifungal prophylaxis, and monitoring for ICANS
MRD testing: Current role in clinical practice and its use as an endpoint for drug approval

This episode is packed with practical, actionable insights for community oncologists managing myeloma day-to-day.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

⁠X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more Rapid Fire Rounds from the Oncology Brothers!

#MultipleMyeloma, #CARTtherapy, #MRD, #CELMoD, #OncologyBrothers

Rapid Fire Rounds - Multiple Myeloma Management with Dr. Joseph Mikhael

Oncology Brothers: Practice-Changing Cancer Discussions

Rapid Fire Rounds - Multiple Myeloma Management with Dr. Joseph Mikhael